The products are slated to be manufactured at the Ankleshwar facility and is expected to start contributing meaningfully to the revenue from FY25
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Lacosamide is indicated to treat partial-onset seizures
The product will be manufactured at Lupin's Pithampur facility in India
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
Subscribe To Our Newsletter & Stay Updated
